Inflammation and Oxidative Stress in Diabetic Nephropathy: New Insights on Its Inhibition As New Therapeutic Targets

Overview

Journal J Diabetes Res

Publisher Wiley

Specialty Endocrinology

Date 2013 Jul 18

PMID 23862164

Citations 87

Authors

Akira Mima

Affiliations

Soon will be listed here.

Abstract

Diabetes and insulin resistance can greatly increase microvascular complications of diabetes including diabetic nephropathy (DN). Hyperglycemic control in diabetes is key to preventing the development and progression of DN. However, it is clinically very difficult to achieve normal glucose control in individual diabetic patients. Many factors are known to contribute to the development of DN. These include diet, age, lifestyle, or obesity. Further, inflammatory- or oxidative-stress-induced basis for DN has been gaining interest. Although anti-inflammatory or antioxidant drugs can show benefits in rodent models of DN, negative evidence from large clinical studies indicates that more effective anti-inflammatory and antioxidant drugs need to be studied to clear this question. In addition, our recent report showed that potential endogenous protective factors could decrease inflammation and oxidative stress, showing great promise for the treatment of DN.

Citing Articles

Relationship of sKlotho with hemoglobin level in patients undergoing maintenance hemodialysis: a case-control study.

Liu Q, Sun Z, Tang X, Yu L, Li S Ther Adv Chronic Dis. 2025; 16:20406223251318481.

PMID: 39959415 PMC: 11829302. DOI: 10.1177/20406223251318481.

Analysis of the potential biological mechanisms of geniposide on renal fibrosis by network pharmacology and experimental verification.

Liu M, Zhao W, Shi R, Wang Z, Li X, Wang D BMC Pharmacol Toxicol. 2025; 26(1):17.

PMID: 39871379 PMC: 11770925. DOI: 10.1186/s40360-025-00855-w.

Unlocking the mechanistic potential of for managing diabetic neuropathy and nephropathy.

Singh S, Singh T J Tradit Complement Med. 2025; 14(6):581-597.

PMID: 39850604 PMC: 11752125. DOI: 10.1016/j.jtcme.2024.04.009.

Challenging directions in pediatric diabetes - the place of oxidative stress and antioxidants in systemic decline.

Lupu V, Miron I, Trandafir L, Jechel E, Starcea I, Ioniuc I Front Pharmacol. 2025; 15:1472670.

PMID: 39744134 PMC: 11688324. DOI: 10.3389/fphar.2024.1472670.

A novel role of peroxiredoxin 2 in diabetic kidney disease progression by activating the classically activated macrophages.

Li X, Long H, Peng R, Zou X, Zuo S, Yang Y Sci Rep. 2024; 14(1):28258.

PMID: 39550424 PMC: 11569199. DOI: 10.1038/s41598-024-79678-4.

References

Wang Y, Lam K, Xu J, Lu G, Xu L, Cooper G . Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem. 2005; 280(18):18341-7. DOI: 10.1074/jbc.M501149200. View

Wu C, Chen J, Lu K, Chen C, Lin S, Chu P . Aberrant cytokines/chemokines production correlate with proteinuria in patients with overt diabetic nephropathy. Clin Chim Acta. 2010; 411(9-10):700-4. DOI: 10.1016/j.cca.2010.01.036. View

Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S . Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J. 2000; 14(3):439-47. DOI: 10.1096/fasebj.14.3.439. View

Shepherd J, Kastelein J, Bittner V, Deedwania P, Breazna A, Dobson S . Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008; 51(15):1448-54. DOI: 10.1016/j.jacc.2007.11.072. View

Okada S, Shikata K, Matsuda M, Ogawa D, Usui H, Kido Y . Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes. 2003; 52(10):2586-93. DOI: 10.2337/diabetes.52.10.2586. View

Mulay S, Gaikwad A, Tikoo K . Combination of aspirin with telmisartan suppresses the augmented TGFbeta/smad signaling during the development of streptozotocin-induced type I diabetic nephropathy. Chem Biol Interact. 2010; 185(2):137-42. DOI: 10.1016/j.cbi.2010.03.008. View

Imani F, Horii Y, Suthanthiran M, Skolnik E, Makita Z, Sharma V . Advanced glycosylation endproduct-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon gamma: role in tissue remodeling. J Exp Med. 1993; 178(6):2165-72. PMC: 2191269. DOI: 10.1084/jem.178.6.2165. View

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

Han J, Thompson P, Beutler B . Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med. 1990; 172(1):391-4. PMC: 2188134. DOI: 10.1084/jem.172.1.391. View

10.

Erdogdu O, Nathanson D, Sjoholm A, Nystrom T, Zhang Q . Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol. 2010; 325(1-2):26-35. DOI: 10.1016/j.mce.2010.04.022. View

11.

Koya D, King G . Protein kinase C activation and the development of diabetic complications. Diabetes. 1998; 47(6):859-66. DOI: 10.2337/diabetes.47.6.859. View

12.

Sakaguchi M, Isono M, Isshiki K, Sugimoto T, Koya D, Kashiwagi A . Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice. Biochem Biophys Res Commun. 2005; 340(1):296-301. DOI: 10.1016/j.bbrc.2005.12.012. View

13.

Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P . Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med. 2000; 342(3):154-60. DOI: 10.1056/NEJM200001203420302. View

14.

Fleischman A, Shoelson S, Bernier R, Goldfine A . Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care. 2007; 31(2):289-94. PMC: 3226794. DOI: 10.2337/dc07-1338. View

15.

Dunlop M . Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int Suppl. 2000; 77:S3-12. DOI: 10.1046/j.1523-1755.2000.07702.x. View

16.

Nathan D, Cleary P, Backlund J, Genuth S, Lachin J, Orchard T . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353(25):2643-53. PMC: 2637991. DOI: 10.1056/NEJMoa052187. View

17.

Newsholme P, Haber E, Hirabara S, Rebelato E, Procopio J, Morgan D . Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity. J Physiol. 2007; 583(Pt 1):9-24. PMC: 2277225. DOI: 10.1113/jphysiol.2007.135871. View

18.

Park C, Kim H, Ko S, Lim J, Ryu G, Chung H . Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol. 2007; 18(4):1227-38. DOI: 10.1681/ASN.2006070778. View

19.

Tarabra E, Giunti S, Barutta F, Salvidio G, Burt D, Deferrari G . Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes. Diabetes. 2009; 58(9):2109-18. PMC: 2731530. DOI: 10.2337/db08-0895. View

20.

Navarro J, Mora C, Muros M, Garcia J . Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Am Soc Nephrol. 2005; 16(7):2119-26. DOI: 10.1681/ASN.2005010001. View